查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863033

依給藥途徑、劑型、藥物類別、通路和最終用戶分類的流感治療藥物市場－2025-2032年全球預測

Influenza Medication Market by Route Of Administration, Form, Drug Class, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，流感治療市場規模將達到 53.9 億美元，複合年成長率為 5.16%。

關鍵市場統計數據
基準年 2024 36億美元
預計年份：2025年 37.9億美元
預測年份 2032 53.9億美元
複合年成長率 (%) 5.16%

全面且策略性地介紹影響現代流感治療決策的臨床因素、給藥方法和操作重點。

流感治療環境的特徵是臨床創新迅速、監管預期不斷變化以及醫療保健服務模式不斷改變，這些因素共同作用，重新定義了製造商、支付方和醫療服務提供者的策略重點。

本摘要整合了目前的臨床重點，例如及時啟動抗病毒治療、抗藥性監測和門診管理等趨勢，以及影響藥物可近性和使用率的實際情況。它重點闡述了藥物類別、給藥方法和通路的進步如何與公共衛生緊急準備和季節性需求波動相互作用。透過以連貫的敘述方式呈現臨床證據、供應鏈考量和相關人員的獎勵，本導言為決策者提供了一個全面的觀點，以完善風險評估、投資優先排序和市場推廣計劃。

本報告始終強調將臨床差異化轉化為營運優勢（處方集定位、醫院庫存通訊協定、門診處方流程）。報告檢驗了藥理特性與分銷管道能力之間的相互作用，並指出了實施過程中的摩擦點和機會。最後，本引言為系統性探討轉型變革、價格影響、市場區隔現況、區域動態、競爭行為以及後續的實用建議奠定了基礎。

深入檢驗正在重塑抗病毒治療模式、獲取途徑和相關人員優先事項的科學、供應鏈和治療路徑變革。

流感格局正經歷著變革性的轉變，這主要得益於科學進步、治療流程的改進以及對藥品供應和配送韌性的重新重視。具有全新作用機制的新型抗病毒藥物正在改變治療模式，而對快速診斷和門診治療的重視也在改變著治療方法的處方和分發地點及方式。

同時，隨著各組織尋求降低中斷風險，生產彈性和策略採購也成為重中之重。吸入和口服製劑的改進以及標靶分子療法的進步，正迫使支付方和醫療服務提供者重新評估治療流程。因此，相關人員越來越重視真實世界療效和抗藥性特徵，而非傳統的療效終點，這正在影響藥物上市決策和臨床指引。

此外，數位醫療技術和不斷發展的分銷管道正在推動以患者為中心的醫療保健模式。遠距醫療、藥品宅配服務和整合式照護路徑支援更早啟動治療，並可能顯著影響需求模式和庫存管理。鑑於這些變化，企業必須採取整合的商業化策略，協調其開發平臺、監管策略和通路拓展，以實現並維持臨床和市場相關性。

深入檢驗2025 年關稅政策帶來的供應鏈趨勢和籌資策略調整，這些政策正在重塑跨境治療藥物採購和庫存策略。

2025年實施的新關稅政策為醫藥產業的跨境供應鏈和籌資策略帶來了顯著的複雜性。關稅調整加劇了國際採購成本的影響，迫使生產者和經銷商重新評估其生產基地、整合供應合約並重新評估本地庫存策略，以維持服務水準並確保產品流通的穩定性。

為此，一些機構正在加快關鍵製造流程的在地化或對替代供應商進行資格認證，以降低關稅波動帶來的風險。另一些機構則正在與下游合作夥伴重新談判商業條款，以便在價值鏈中更公平地分攤新增成本。這些調整凸顯了彈性合約、雙重採購和庫存緩衝的重要性，它們能夠幫助吸收關稅引起的成本波動，同時確保臨床供應不會中斷。

此外，採購團隊和政策相關人員在重新評估競標和採購框架，以反映新的到岸成本實際情況。對市場參與企業而言，實際影響包括：在國際物流中，情境規劃和壓力測試的重要性日益凸顯；以及對監管協調的重新關注，這將有助於簡化成品製劑和原料藥的跨境運輸。最終，海關情勢凸顯了供應鏈韌性作為商業規劃關鍵要素的策略價值。

將給藥途徑、製劑細微差別、藥物類別區分、分銷管道和最終用戶路徑等因素與策略決策槓桿聯繫起來的詳細細分洞察

詳細的細分分析揭示了給藥途徑、劑型、藥物類別、分銷管道和最終用戶環境的不同臨床、商業性和營運影響，這些因素共同決定了產品定位和通路策略。

在評估給藥途徑時，利害關係人應考慮以下幾點：吸入給藥可使藥物快速到達肺部標靶；靜脈注射是重症監護和住院治療的重要選擇；口服給藥則方便門診病人使用。口服給藥方面，混懸液和藥片的差異會影響患者的遵從性、兒童用藥劑量和配藥流程。就劑型而言，注射劑仍然是住院治療的核心，而吸入粉劑則用於門診給藥。混懸劑可靈活調整兒童和吞嚥困難患者的用藥劑量，而片劑則涵蓋了金剛烷胺、巴洛沙韋酯、奧司他韋和利馬他定等多種藥物，這對處方趨勢和庫存管理具有重要意義。

從藥物類別角度來看，核酸內切酶抑制劑具有新穎的作用機制，影響抗藥性與合併用藥策略。 M2離子通道抑制劑，包括金剛烷胺和利巴韋林，由於其特定的歷史抗藥性和安全性特徵，目前在某些特定情況下使用受到限制。神經氨酸酶抑制劑，包括奧司他韋、帕拉米韋和扎那米韋，是目前抗病毒治療的基石，尤其是在能夠早期給藥的情況下。通路分析突顯了醫院藥房作為患者照護和急診護理基石的重要作用；在線藥房為患者提供直接便捷的用藥途徑；以及零售藥房作為季節性需求和藥劑師主導的諮詢服務的主要患者接觸點。最後，終端使用者細分突顯了居家照護在早期啟動治療和依從性支持方面日益成長的重要性；醫院在急性護理和重症病例管理方面的重要性；以及門診診所作為診斷、啟動治療和後續觀察的關鍵樞紐的重要性。每種環境都會影響庫存管理政策、包裝選擇和病患教育需求。

對這些相互關聯的細分維度進行整體考慮，將指導商業化選擇，從包裝和分發形式到通路夥伴關係和有針對性的醫學事務計劃，並且在設計上市和生命週期策略時應進行整體考慮。

在製定打入市場策略，要從全面的區域觀點出發，協調美洲、歐洲、中東和非洲以及亞太地區的監管、分銷和臨床實踐差異。

區域趨勢持續對全球流感藥物的取得、監管和採用模式產生決定性影響，因此需要製定細緻入微、因地制宜的策略，使臨床證據與分銷能力和支付方的期望相一致。

在美洲，完善的門診病人基礎設施、一體化的零售藥房網路和強大的居家醫療服務為口服抗病毒藥物和以藥屋主導的治療啟動途徑創造了機會。診斷的可近性和支付方的覆蓋模式進一步影響藥物的普及趨勢。在歐洲、中東和非洲，不同的監管路徑和不同的報銷體係要求採取靈活的實施方案，兼顧各國的藥品目錄和區域臨床指南。同時，該地區的一些市場正在投資擴大住院床位並實現供應鏈現代化，以加強應對疫情的能力。在亞太地區，數位健康工具的快速普及、對本地生產投資的增加以及社區護理模式的高普及率，都為多元化的分銷策略提供了支持，該策略可以根據當地的處方習慣，優先提供吸入劑和口服液劑型。

在所有地區，相關人員必須調整產品定位，以反映診斷基礎設施、藥師執業範圍和支付體系的差異。此外，以抗菌藥物管理和抗藥性監測為重點的區域政策也日益影響治療方案和處方集決策。因此，採取因地制宜的方法，使臨床訊息、供應策略和通路合作與當地系統實際情況相符，對於確保藥物的持續可及性和使用率至關重要。

透過策略性企業行動和能力投資，在研發、製造、數位化夥伴關係以及通路特定的商業化模式方面實現差異化。

企業行動和策略姿態決定了流感治療領域藥物發現、開發、生產和商業化活動的競爭格局。

主要企業正優先建構兼顧近期商業機會與對新型作用機制和聯合治療進行長期投資的產品組合。生物製藥開發商、專業製造商和診斷服務提供者之間的策略聯盟正在加速整合價值提案，將抗病毒療法與快速就地檢驗和患者分流服務相結合。在生產方面，企業正投資於模組化、多地點的生產能力，以提高靈活性並降低對單一供應來源的依賴風險。同時，品質和供應連續性計劃在董事會層面也變得日益重要。

在商業方面，他們正在完善主導細分市場為導向的市場推廣模式，以最佳化針對醫院處方集委員會、零售藥房網路和數位健康平台的訊息。醫學事務團隊在生命週期管理中發揮核心作用，提供實證醫學證據和真實世界結果研究，以幫助解決抗藥性問題和療效比較問題。一些機構也正在探索差異化包裝、病患援助解決方案和依從性技術，以增強門診病人的連續性和價值。這些企業層面的努力正在重塑競爭優勢，使其從純粹以產品為中心的差異化轉向涵蓋診斷、供應穩定性和管道驅動的患者獲取途徑的整合解決方案。

為領導者提供切實可行的、優先排序的建議，以協調臨床差異化與供應鏈韌性、通路最佳化和循證市場進入策略。

我們鼓勵產業領導者採取一系列切實可行的舉措，將臨床差異化、營運韌性和通路最佳化相結合，以幫助創造價值並改善患者預後。

首先，將抗藥性監測和真實世界療效終點納入研發和上市後證據計劃，以確保治療定位能夠適應不斷變化的臨床實踐。其次，推動供應鏈多元化，並對關鍵供應商進行在地化合格，以最大限度地降低關稅和物流衝擊帶來的風險。雙重採購和應急庫存應納入情境規劃。第三，設計包裝和劑型時，應充分考慮居家醫療、醫院和門診等不同環境下最終使用者的需求，優先考慮兒童和老年患者的易用性。第四，加強與診斷服務提供者和數位平台的合作，加速治療啟動，並制定能夠提高患者依從性和治療效果的綜合護理路徑。第五，制定符合當地醫保報銷體系的市場進入策略，使臨床文件符合支付方的證據要求，並酌情儘早與衛生技術評估機構接洽。

最後，需要投資於有針對性的商業性能力，例如藥房協作團隊、數位化病患援助和按績效付費合約方面的專業知識，才能將臨床價值轉化為處方集的採納和持續採納。透過實施這些建議，管理者可以提高流感藥物的臨床和商業性績效，同時最大限度地降低營運風險。

本報告的調查方法透明且以證據主導，結合了專家訪談、系統性的二手研究和情境三角驗證，以檢驗研究結果和建議。

本報告的調查方法結合了多方面的證據綜合、專家對話和系統性檢驗，以確保得出可靠的實用結論。

初步研究包括對臨床醫生、藥屋主任、供應鏈主管和支付方代表進行深度訪談，以解讀臨床實踐、處方集使用情況和採購趨勢。次要研究包括對同行評審的臨床文獻、監管指導文件、公共衛生建議和產品標籤進行系統性回顧，以深入了解藥物作用機制和安全性概況。分析還整合了通路和臨床試驗點的營運數據，以將臨床特徵與實際應用中的挑戰聯繫起來。

研究結果透過跨部門研討會和敏感度分析進行三角驗證，以檢驗假設並確定替代情境。對於存在不確定性，例如抵抗趨勢的變化和政策的調整，研究明確提出了保留意見，並記錄了方法選擇，以確保透明度。最終形成的方法論優先考慮基於證據的解釋、相關人員的檢驗以及考慮情境的建議，為短期戰術性選擇和長期策略規劃提供參考。

最終整合凸顯了臨床創新、供應鏈韌性和分銷策略的整合執行，以確保患者能夠獲得治療並展現患者獲益。

總之，流感治療生態系統正處於一個轉折點，科學創新、不斷發展的通路和供應韌性正在匯聚，重新定義價值鏈上相關人員的策略要務。

該報告的綜合視角強調，成功的專案需要將臨床差異化和營運前瞻性相結合：將新穎的作用機制和易於使用的製劑與穩健的分銷策略和循證實踐計劃相結合。由於區域差異和關稅，供應壓力日益複雜，因此，靈活選擇製造地並與支付方和醫療服務提供者密切合作至關重要。積極整合診斷夥伴關係、加強與藥房的合作並優先考慮真實世界證據生成的公司，將更有利於展現產品價值，並確保在各種醫療環境中實現永續的藥物可及性。

歸根結底，前進的方向在於整合實施——協調研發選擇、商業模式和供應鏈策略，以加快及時獲取藥物，管理抗藥性風險，並為患者和醫療保健系統帶來可衡量的收益。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 採用mRNA平台技術開發通用流感疫苗
  • 將數位健康工具整合到流感治療依從性監測中
  • 非處方抗病毒藥物和快速家用檢測套組的結合推動了成長
  • 針對高風險患者流感病毒蛋白的單株抗體療法取得進展
  • 製藥公司與生技Start-Ups進行策略合作，共同開發下一代流感疫苗
  • 引入人工智慧驅動的預測模型，用於最佳化季節性流感疫苗株的選擇
  • 增加對有針對性的流感預防藥物的投資，以滿足兒童和老年人的需求。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依給藥途徑分類的流感藥物市場

  • 吸入
  • 靜脈注射
  • 口服
    • 暫停
    • 藥片

第9章 流感藥物市場（依劑型分類）

  • 注射
  • 粉末吸入劑
  • 暫停
  • 藥片
    • 金剛烷胺
    • 巴洛沙韋酯
    • 奧司他韋
    • 金剛烷胺

第10章 流感藥物市場（依藥物類別分類）

  • 核酸內切酶抑制劑
  • M2離子通道抑制劑
    • 金剛烷胺
    • 金剛烷胺
  • 神經氨酸酶抑制劑
    • 奧司他韋
    • 帕拉米韋
    • 扎那米韋

第11章 流感藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 流感藥物市場（依最終用戶分類）

  • 居家醫療
  • 醫院
  • 門診部

第13章 各地區流感藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 流感藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國流感藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • CSL Seqirus Pty Ltd
    • Sanofi Pasteur SA
    • AstraZeneca plc
    • Shionogi & Co., Ltd
    • BioCryst Pharmaceuticals, Inc.
    • Cipla Ltd
    • Teva Pharmaceutical Industries Ltd
    • Sandoz International GmbH
Product Code: MRR-F6513A06BE18

The Influenza Medication Market is projected to grow by USD 5.39 billion at a CAGR of 5.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.60 billion
Estimated Year [2025] USD 3.79 billion
Forecast Year [2032] USD 5.39 billion
CAGR (%) 5.16%

A comprehensive and strategic introduction framing clinical drivers, delivery modalities, and operational imperatives that shape modern influenza therapeutic decision-making

The influenza therapeutic environment is characterized by rapid clinical innovation, evolving regulatory expectations, and shifting patterns of care delivery that together redefine strategic priorities for manufacturers, payers, and providers.

This summary synthesizes the current clinical imperatives-such as timely antiviral initiation, resistance monitoring, and outpatient management trends-alongside the operational realities that shape access and uptake. It highlights how advances in drug classes, delivery modalities, and distribution channels are intersecting with public health preparedness and seasonal demand variability. By placing clinical evidence, supply chain considerations, and stakeholder incentives in one coherent narrative, the introduction equips decision-makers with a holistic vantage point from which to assess risk, prioritize investment, and refine go-to-market planning.

Throughout the report, emphasis is placed on translating clinical differentiation into operational levers: formulary positioning, hospital stocking protocols, and outpatient prescribing workflows. The interplay between pharmacological attributes and channel capabilities is explored to identify friction points and opportunities for adoption. Ultimately, this introduction lays the foundation for a structured exploration of transformative shifts, tariff impacts, segmentation realities, regional dynamics, competitive behaviors, and practical recommendations that follow.

An in-depth review of scientific, supply chain, and care pathway shifts that are reshaping antiviral treatment patterns, access models, and stakeholder priorities

The influenza landscape is undergoing transformative shifts driven by scientific advances, care pathway evolution, and a renewed focus on resilience in supply and delivery. Emerging antiviral classes with novel mechanisms of action are changing treatment paradigms, while the renewed emphasis on rapid diagnostics and outpatient care is reshaping where and how therapies are prescribed and dispensed.

Concurrently, manufacturing agility and strategic sourcing have moved to the forefront as organizations seek to mitigate disruption risks. The convergence of improved inhalation and oral formulations, coupled with targeted molecular therapies, is prompting payers and providers to reassess treatment algorithms. As a result, stakeholders are increasingly prioritizing real-world effectiveness and resistance profiles over traditional efficacy endpoints, thereby influencing formulary decisions and clinical guidelines.

Additionally, digital health enablers and evolving distribution channels are facilitating more patient-centric models of care. Remote consultations, pharmacy home delivery services, and integrated care pathways support earlier initiation of therapy, which can materially affect demand patterns and stock management. Taken together, these shifts require companies to adopt integrated commercialization approaches that align R&D pipelines, regulatory strategies, and channel engagement to capture and sustain clinical and market relevance.

A detailed examination of 2025 tariff-driven supply chain dynamics and procurement adaptations that are reshaping cross-border sourcing and inventory strategies for therapeutics

The introduction of new tariff policies in 2025 has introduced material complexity into cross-border pharmaceutical supply chains and procurement strategies. Tariff adjustments have amplified the cost implications of international sourcing, prompting manufacturers and distributors to reassess production footprints, aggregate supply agreements, and local inventory strategies in order to preserve service levels and maintain predictable product flows.

In response, some organizations have accelerated localization of critical manufacturing steps or qualified alternate suppliers to reduce exposure to tariff volatility. Others have renegotiated commercial terms with downstream partners to distribute incremental costs more equitably across the value chain. These adaptations have emphasized the importance of flexible contracting, dual-sourcing, and inventory buffers to absorb tariff-induced cost movements without disrupting clinical availability.

Moreover, procurement teams and policy stakeholders are re-evaluating tender and purchasing frameworks to reflect new landed-cost realities. The practical consequence for market participants is a heightened emphasis on scenario planning and stress testing for international logistics, as well as a renewed focus on regulatory harmonization that can simplify cross-border movement of finished dosage forms and APIs. Ultimately, the tariff landscape has underscored the strategic value of supply chain resilience as an integral component of commercial planning.

Detailed segmentation insights connecting route of administration, formulation nuances, drug class differentiation, distribution channels, and end-user pathways to strategic decision levers

A granular segmentation lens reveals distinctive clinical, commercial, and operational implications across routes, forms, drug classes, distribution channels, and end-user settings that collectively inform product positioning and channel strategy.

When evaluating Route Of Administration, stakeholders must consider Inhalation as a modality that supports rapid pulmonary delivery for targeted effect, Intravenous as a critical option for severe cases and inpatient settings, and Oral treatments that cater to outpatient convenience; within Oral, the differentiation between Suspension and Tablet formulations affects adherence, pediatric dosing, and dispensing workflows. In terms of Form, Injection remains central to hospitalized care pathways while Powder Inhaler supports ambulatory administration; Suspension formulations enable flexible dosing for children and patients with swallowing difficulties, and Tablet formats encompass a portfolio that includes Amantadine, Baloxavir Marboxil, Oseltamivir, and Rimantadine with important implications for prescribing preferences and stock management.

From a Drug Class perspective, Endonuclease Inhibitors represent a newer mechanism with implications for resistance management and combination strategies; M2 Ion Channel Inhibitors encompass Amantadine and Rimantadine and carry a specific historical resistance and safety profile that limits their contemporary use in certain contexts; Neuraminidase Inhibitors include Oseltamivir, Peramivir, and Zanamivir and remain a cornerstone of current antiviral toolkits, particularly where early administration is feasible. Distribution Channel analysis highlights Hospital Pharmacy as the fulcrum for inpatient care and emergency treatment, Online Pharmacy as an accelerating conduit for direct-to-patient access and convenience, and Retail Pharmacy as the primary patient-facing touchpoint for seasonal demand and pharmacist-led counseling. Lastly, End User segmentation underscores that Home Care is increasingly important for early treatment initiation and adherence support, Hospitals represent acute care and severe case management, and Outpatient Clinics serve as critical points for diagnosis, initiation of therapy, and follow-up-each setting shaping stocking decisions, packaging choices, and patient education needs.

Taken together, these interlocking segmentation dimensions guide commercialization choices, from packaging and dispensing formats to channel partnerships and targeted medical affairs programs, and should be considered holistically when designing launch and lifecycle strategies.

Comprehensive regional perspective that aligns regulatory, distribution, and clinical practice differences across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform market entry strategies

Regional dynamics continue to exert a defining influence on access, regulation, and adoption patterns across the global influenza therapeutic landscape, requiring nuanced regional strategies that align clinical evidence with distribution capabilities and payer expectations.

In the Americas, established outpatient infrastructures, integrated retail pharmacy networks, and strong home-care services create opportunities for orally administered antivirals and pharmacy-led initiation pathways; diagnostic availability and payer coverage models further shape adoption dynamics. In Europe, Middle East & Africa, variable regulatory pathways and heterogeneous reimbursement systems necessitate flexible launch approaches that account for national formularies and local clinical guidelines, while some markets in the region are investing in expanded inpatient capacities and supply chain modernization to strengthen pandemic preparedness. In the Asia-Pacific region, fast-moving adoption of digital health tools, rising investments in local manufacturing, and a high prevalence of community-based care models support diversified distribution strategies that can emphasize both inhalation and oral solution access depending on local prescribing habits.

Across all regions, stakeholders should calibrate product positioning to reflect differences in diagnostic infrastructure, pharmacist scope of practice, and payer arrangements. Moreover, regional policy initiatives focused on antimicrobial stewardship and resistance surveillance are increasingly shaping therapeutic choice and formulary decisions. Consequently, a regionally adaptive approach-one that aligns clinical messaging, supply strategies, and channel engagement with local system realities-will be essential for sustained access and uptake.

Strategic company behaviors and capability investments that are driving differentiation across R&D, manufacturing, digital partnerships, and channel-focused commercialization models

Company behaviors and strategic postures are defining competitive dynamics across discovery, development, manufacturing, and commercialization activities in the influenza therapeutics arena.

Leading firms are prioritizing portfolios that balance near-term commercial opportunities with longer-term investments in novel mechanisms and combination therapies. Strategic partnerships between biologics developers, specialty manufacturers, and diagnostic providers are accelerating integrated value propositions that tie antiviral therapies to rapid point-of-care testing and patient triage services. On the manufacturing front, firms are investing in modular and multi-site production capabilities to enhance flexibility and reduce single-source vulnerabilities, while quality and supply continuity programs are being elevated to board-level attention.

Commercially, companies are refining segmentation-driven go-to-market models that tailor messaging to hospital formulary committees, retail pharmacy networks, and digital health platforms. Medical affairs teams are increasingly central to lifecycle management, providing evidence generation and real-world outcomes studies that support positioning in the face of resistance concerns and comparative effectiveness questions. Some organizations are also exploring differentiated packaging, patient support solutions, and adherence technologies to strengthen outpatient persistence and therapeutic value. Collectively, these company-scale actions are reshaping competitive advantage from purely product-centric differentiation toward integrated solutions that span diagnostics, supply robustness, and channel-enabled patient access.

Actionable and prioritized recommendations for leaders to align clinical differentiation with supply resilience, channel optimization, and evidence-driven market access strategies

Industry leaders should adopt a set of pragmatic, actionable moves that align clinical differentiation with operational resilience and channel optimization to capture value and support improved patient outcomes.

First, embed resistance surveillance and real-world effectiveness endpoints into development and post-launch evidence plans so that therapeutic positioning responds to evolving clinical practice. Second, pursue supply chain diversification and local qualification of key suppliers to minimize exposure to tariff and logistics shocks; dual-sourcing and contingency inventories should be part of scenario planning. Third, design packaging and dosing formats that reflect end-user needs across home care, hospitals, and outpatient clinics, ensuring that pediatric and geriatric usability considerations are prioritized. Fourth, cultivate partnerships with diagnostic providers and digital platforms to accelerate timely initiation of therapy and to create bundled care pathways that improve adherence and outcomes. Fifth, tailor regional market access strategies to local reimbursement frameworks, aligning clinical dossiers with payer evidence requirements and engaging early with health technology assessment bodies when applicable.

Finally, invest in targeted commercial capabilities-such as pharmacy engagement teams, digital patient support, and outcome-based contracting expertise-that can translate clinical value into formulary acceptance and sustained uptake. By implementing these recommendations, leaders can minimize operational risk while enhancing the clinical and commercial performance of influenza therapeutics.

A transparent, evidence-driven methodology integrating primary expert interviews, systematic secondary research, and scenario triangulation to validate findings and recommendations

The research methodology underpinning this report combines multi-source evidence synthesis, expert engagement, and systematic validation to ensure robust and actionable conclusions.

Primary research included in-depth interviews with clinicians, pharmacy directors, supply chain executives, and payer representatives to ground interpretations of clinical practice, formulary behavior, and procurement dynamics. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, public health advisories, and product labeling to corroborate mechanism-of-action insights and safety profiles. The analysis also integrated operational data on distribution channels and care settings to link clinical attributes with real-world execution challenges.

Findings were triangulated through cross-functional workshops and sensitivity analysis to test assumptions and surface alternative scenarios. Where uncertainties existed-such as evolving resistance trends or policy shifts-clear caveats were included and methodological choices were documented to support transparency. The result is a methodological approach that prioritizes evidence-backed interpretation, stakeholder validation, and scenario-aware recommendations to inform both near-term tactical choices and longer-term strategic planning.

A conclusive synthesis emphasizing integrated execution across clinical innovation, supply resilience, and channel strategies to secure access and demonstrable patient benefit

In conclusion, the influenza therapeutic ecosystem is at an inflection point where scientific innovation, channel evolution, and supply resilience converge to redefine strategic imperatives for stakeholders across the value chain.

The synthesis presented here underscores that successful programs will marry clinical differentiation with operational foresight: aligning novel mechanisms and user-friendly formulations with robust distribution strategies and evidence-generation plans. Regional nuances and tariff-driven supply pressures add layers of complexity that necessitate adaptive manufacturing footprints and close collaboration with payers and providers. Companies that proactively integrate diagnostic partnerships, strengthen pharmacy engagement, and prioritize real-world evidence generation will be better positioned to demonstrate value and secure sustainable access in diverse care settings.

Ultimately, the path forward is one of integrated execution-where R&D choices, commercial models, and supply chain strategies are orchestrated to accelerate timely access, manage resistance risk, and deliver measurable benefits for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of mRNA platform technology for universal influenza vaccine development
  • 5.2. Integration of digital health tools in influenza treatment adherence monitoring
  • 5.3. Growth of over-the-counter antiviral medications combined with rapid home testing kits
  • 5.4. Advances in monoclonal antibody therapies targeting influenza viral proteins among high-risk patients
  • 5.5. Strategic partnerships between pharmaceutical companies and biotech startups for next-generation flu vaccines
  • 5.6. Implementation of AI-driven forecasting models for selecting optimal seasonal influenza vaccine strains
  • 5.7. Rising investment in targeted influenza prophylactics addressing pediatric and geriatric population needs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Medication Market, by Route Of Administration

  • 8.1. Inhalation
  • 8.2. Intravenous
  • 8.3. Oral
    • 8.3.1. Suspension
    • 8.3.2. Tablet

9. Influenza Medication Market, by Form

  • 9.1. Injection
  • 9.2. Powder Inhaler
  • 9.3. Suspension
  • 9.4. Tablet
    • 9.4.1. Amantadine
    • 9.4.2. Baloxavir Marboxil
    • 9.4.3. Oseltamivir
    • 9.4.4. Rimantadine

10. Influenza Medication Market, by Drug Class

  • 10.1. Endonuclease Inhibitors
  • 10.2. M2 Ion Channel Inhibitors
    • 10.2.1. Amantadine
    • 10.2.2. Rimantadine
  • 10.3. Neuraminidase Inhibitors
    • 10.3.1. Oseltamivir
    • 10.3.2. Peramivir
    • 10.3.3. Zanamivir

11. Influenza Medication Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Influenza Medication Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Outpatient Clinics

13. Influenza Medication Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Influenza Medication Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Influenza Medication Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Hoffmann-La Roche AG
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. CSL Seqirus Pty Ltd
    • 16.3.4. Sanofi Pasteur SA
    • 16.3.5. AstraZeneca plc
    • 16.3.6. Shionogi & Co., Ltd
    • 16.3.7. BioCryst Pharmaceuticals, Inc.
    • 16.3.8. Cipla Ltd
    • 16.3.9. Teva Pharmaceutical Industries Ltd
    • 16.3.10. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA INFLUENZA MEDICATION MARKE